申请人:Ungashe Solomon
公开号:US20060111351A1
公开(公告)日:2006-05-25
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
提供了作为CCR9受体的有效拮抗剂的化合物,并在动物炎症测试中进一步确认了其效果,这是CCR9的标志性疾病状态之一。这些化合物通常是芳基磺酰胺衍生物,可用于制备药物组合物,治疗CCR9介导的疾病的方法,并作为CCR9拮抗剂鉴定的检测中的对照。